Please ensure Javascript is enabled for purposes of website accessibility

Fear Takes Grip of Intrexon and Refuses to Let Go

By Sean Williams - Sep 28, 2015 at 3:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Intrexon shares have been pummeled following the unveiling of Hillary Clinton's prescription drug reform proposal last week. Should you be worried as well?

What: Shares of Intrexon (PGEN -0.80%), a mid-cap biotechnology platforms company that's focused on developing gene-based programs to combat serious diseases, such as cancer, tumbled as much as 22% today (and 30% for the past week) as a continuation move following the unveiling of presidential hopeful Hillary Clinton's drug plan last week.

So what: Fear as a whole has gripped the majority of the biotech sector, but Intrexon could find itself squarely in the crosshairs of Clinton's prescription drug reform proposal. Intrexon and its development partner Ziopharm Oncology (ZIOP 0.71%) are developing treatments that can turn rapidly turn off gene expression, and potentially slow certain types of cancers. Their leading collaboration is a midstage study involving Ad-RTS-IL-12 that's being tested as a treatment for breast cancer. Because these treatments are highly specialized, if Ad-RTS-IL-12 were approved by the Food and Drug Administration it would likely command a hefty price tag.

As a refresher, Clinton's proposal would cap out-of-pocket expenses for covered prescriptions at $250 per month, eliminate Medicare's inability to negotiate drug prices, and would allow cheaper medications to be imported into the United States. Viewed as one of a handful of potential frontrunners to the White House in 2016, investors are obviously fearful that prescription drug reform could become a hot-button issue in this election.

Now what: The $64,000 question is whether or not you should allow the fear that's gripped most of the biotechnology sector to get to you as well. Personally, I haven't seen anything in any lawmakers' proposals that suggest true prescription reform is coming our way anytime soon. I'm not saying that some level of reform may not be needed, but the chances of effective reform being implemented in the next year or two still seems to be somewhat of a longshot.

Instead, investors should be wholly focused on the Intrexon-Ziopharm collaboration and be monitoring the progress of Ad-RTS-IL-12, which is utilizing Intrexon's proprietary RheoSwitch technology and can regulate the timing and dose of an activator ligand. It's possible this research could represent a new and successful pathway to treating cancer, but we probably won't know a lot until we get some broader-based efficacy data in later-stage studies. For now I'd suggest watching patiently from the sidelines, but I see no harm in having Intrexon squarely on your watchlist.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Precigen, Inc. Stock Quote
Precigen, Inc.
$1.24 (-0.80%) $0.01
ZIOPHARM Oncology, Inc. Stock Quote
ZIOPHARM Oncology, Inc.
$0.50 (0.71%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.